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Abstract: This paper discusses recent advances in therapy of atopic
dermatitis (AD), excluding those that include dietary management. Some
of these therapies are anecdotal, experimentai, or somewhat controver-
siai. It is important to emphasize that physicians should not try what is
new without first having given standard therapy a iong and reasonabie
chance to succeed. This is important because AD does not last forever,
and in many patients, miid disease heals spontaneously.
Rajka (1) believed that most cases of infantile
atopic dermatitis (AD) heal at 2 to 3 years of age.
Patients with widespread, severe involvement and
those in whom the condition persists past the sixth
year of age have a much worse prognosis. Roth and
Kierland (2) conducted a 20-year follow-up on ap-
proximately 200 adult patients; 40% of those with
mild AD had cleared, but only 29% of those with
severe disease were similarly uninvolved.
STANDARD THERAPY
Standard therapy should be directed toward con-
trolling the dryness, erythema, and pruritus that
characterize AD in all patients at all ages. I believe
that in order to ensure compliance, it should be sim-
ple and consist of only three or four basic items. My
standard therapy uses mild to moderate corticoste-
roids (1% hydrocortisone or 0.025%-0.I% triamci-
nolone), daily bathing, avoidance of harsh soaps,
and the liberal use of light to heavy lubricants de-
pending on the season and the patient's tolerance. I
insist that patients comply thoroughly with such a
regimen before venturing into more difficult ther-
apy. Giving patients complex instructions for mod-
ification of diet, pet control, means to increase the
household humidity, avoidance of inhalants, avoid-
ance of woolens, and major changes in bathing hab-
its are usually too overwhelming and confusing to
be attempted on the first visit. Information sheets
are very useful for patients and parents.
Topical steroids should never be applied more
than two to three times a day, whereas lubricants
can be applied as needed for dryness. For patients
whose disease is particularly severe, it is often more
effective to begin with a one- to two-week course of
the most potent topical corticosteroid available, fol-
lowed by a gradual taper to low- to intermediate-
potency agents. This often gives an immediate burst
of relief, which can then be maintained with less
strong drugs. Many physicians frequently use corti-
costeroids that are far too mild to obtain any thera-
peutic benefit.
Oral antihistamines, in my experience, are re-
markably ineffective for the long-term management
of AD. Their initial usefulness is soon overcome by
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rapid development of tolerance, and I use them pri-
marily as sedatives at bedtime.
It is important to establish realistic therapeutic
goals and emphasize that AD cannot be cured. Far
too many patients and parents believe that there is a
"penicillin shot" that will provide long-lasting re-
lief. 1 also emphasize that usually no laboratory
tests are useful in routine management of the condi-
tion.
It is much better to insist on compliance with ba-
sic therapy before switching to more advanced ther-
apy. Ifxerosis is not controlled, AD will not usually
improve.
ADVANCED THERAPY
Recent advances have been reported in the use of
ultraviolet (UV) light; degerming infected skin; use
of oil of evening primrose and eicosapentenoic acid
(EPA), cyclosporine, chloroquin, and phosphodi-
esterase inhibitors; and avoiding the house dust
mite.
Systemic Steroids
If the patient does not respond to outpatient therapy
with mild topical steroids, lubricants, and antihis-
tamines, and if the disease appears itiflammatory (as
opposed to lichenified), I consider a short course of
ora! corticosteroids (prednisone, 1 mg/kg) for five to
seven days. This drug is far too toxic to be used on
a long-term basis except for those with life-threat-
ening eczema and asthma.
Recently, Atherton's group (3) proposed a novel
method of combining inhaled beclomethasone
diproprionate plus the same agent given orally. In a
placebo-controlled trial, 26 children with severe
atopic eczema responded significantly better while
receiving active agent than placebo. Skin involve-
ment improved by about a half and there was a par-
allel reduction in itch. The authors obtained evi-
dence of only very mild adrenal suppression. They
believed the drug may be working at the local level
of the gut to decrease gastrointestinal permeability
to antigens.
UV Light
If topical and systemic corticosteroids together with
lubricants and antihistamines do not produce a sat-
isfactory response, the patient should be admitted
to the hospital for a course of UV light similar to a
modified Goekerman. Falk (4) evaluated 106 pa-
tients with atopic dermatitis who were given either
ultraviolet B (UVB) or a combination of A and B
(UVAB). Ninety-four percent of 54 patients who re-
ceived UVAB were in remission after 18 treat-
ments, compared to otily 84% of 52 patients who
received UVB after 23 treatments. This difference
was statistically significant (/" < 0.01). Neither
treatment produced long-term responses. Thirty of
44 who were given UVB relapsed within three
months after the last treatment, as did 27 of 51 who
had UVAB.
Similar results were obtained in a smaller group
of 56 patients studied by Midelfart, Stenvold, and
Voloden (5). Thirty-three with severe AD were
treated with UVB alone and 23 with UVAB. Forty-
eight percent of the latter achieved complete remis-
sion compared to 27% of the former.
Atherton et al (6) treated 15 adolescents with se-
vere eczema with psoralen, 0.6 mg/kg administered
either two or three times a week. Patients also
received 1 J/cm^ UVA, with the dose gradtially in-
creasing by increments of 0.5 to 2.0 Jlcm^ at inter-
vals of not less than one week, depending on skin
tolerance and response. Fourteen of the 15 patients
achieved near clearance, which took from 10 to 25
weeks (median 16 wks). Long-term remission was
induced in nine.
Of the seven children with adeqtiate data, six had
growth velocity below the third percentile. During
and after PUVA treatment, ail six achieved growth
velocity between the fiftieth and ninety-seventh
percentiles.
Controlling Infection
Acute or flaring AD is frequently considered to
have an infectious component. Numerous studies
have shown that the skin of children with the con-
dition is heavily colonized with coagtilase-positive
Staphylococcus aureus. Such was the case in both
the involved and uninvolved skin of one group of
patients studied by Leyden, Marples, and Kligman
(7). Wet lesions of AD carry a tremendous burden
of organisms, with lesser amounts being found in
the dry, lichenified areas and smaller quantities
present in clinically normal skin. The exact role of
these organisms in the etiology of AD is not known
for certain, but there may be an infectious and an
allergenic component.
David and Cambridge (8) followed 190 children
with AD prospectively for two and a half years.
Seventy-six (40%) had exacerbations of eczema due
to bacterial infection and 25 (15%) were admitted to
hospital. Staphylococcus aureus was the most com-
monly recovered organism, being found in 97% of
patients.
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Welboum, Champion, and Parish, in a series of
three classic papers (9-11), evaluated 122 patients
with eczematous dermatitis. They showed a high
percentage had immediate or four-hour (Arthuslike)
responses to intradermal skin tests with staphylo-
coccal antigen. In addition, the antigen was present
on the skin surface and in the dermis, indicating
percutaneous absorption. Approximately 60% of
the patients had circulating antistaphylococcal im-
munoglobulin that was thought to participate in this
hypersensitivity reaction.
Lever et al evaluated 49 patients with AD in
a double-blind, placebo-controlled, crossover trial
of mupirocin, a topical antistaphylococcal antibiotic
(12). All patients had heavy colonization of the skin
with S. aureus prior to therapy. The bacterial count
was sigtiificantly reduced by two weeks treatment
with topical mupirocin twice a day, but not by the
placebo. This reduction was accompatiied by signif-
icant improvement in clinical severity, which was
maintained over four weeks after therapy even
though recolonization occtirred during this period.
Despite recolonization, clinical values remained im-
proved and no serious side efifects were observed.
Many of the new imidazole group of antifungal
agents are also potent antibacterial s. White and
Blatchford (13) studied 19 patients with severe
atopic eczema, who were treated with 2% micona-
zole plus 1% hydrocortisotie cream for 14 days.
Seventeen (89%) demonstrated a significant im-
provement, and the combination was rated by 68%
of the patients as better than previous therapy. Im-
petigo and ecthyma have also been successftilly
treated using the topical antifungats miconazole and
sulconazole (14).
It is also generally accepted that the oral sys-
temic antibiotics are useful for acute, weeping flares
of AD, particularly those that appear to be secon-
darily infected. There are no long-term studies on the
degree of benefits from such therapy, and readers
should always be aware of the potential for devel-
opment of resistance after both topical and systemic
therapy. Somewhat limiting the usefulness of the
imidazoles and mupirocin is their relatively high
cost for the small package.
Dietary Supplementation with Oii of Evening
Primrose and Eicosapentenoic Acid
Wright and Burton (15) were among the first to con-
duct a double-blind, controlled, crossover study oi
various doses of oral evening primrose oil (EPO).
They evaluated 99 patients with atopic eczema.
Sixty adults received two, four, or six capstiles
twice daily, while 39 children (8 mo-I4 yrs of age)
received one or two capsules twice a day. Each cap-
sule contained 360 mg of linoleic acid and 45 mg of
gamma-linolenic acid. The brand name Efamol was
used throughout this study. In the low-dose groups
in children and adults, no objective improvements
were noticed, but patients did feel that pruritus was
improved compared to placebo (P < 0.05). In the
higher-dose groups, Efamol was better than placebo
with regard to improvement in itch, scaling, and
general severity. These responses occurred most
prominently in the adults and less so among chil-
dren. Adtilt patients in the high-dose group noted an
overall improvement in severity of about 43%. No
side effects were reported. The authors felt that the
mode of action was uncertain but that it might in-
volve prostaglandin synthesis and the regtilation of
T lymphocytes.
A somewhat similar study was carried out by a
Finnish group (16) who evaluated 25 patients with
atopic eczema treated with either EPO (n = 14) or
placebo (n = 11) for 12 weeks. Patients receiving
EPO noted a statistically significant reduction in the
severity and grade of inflammation as well as the
percentage of body surface area involved. In addi-
tion, they felt less itchy and were perceived to be
less dry. The oil caused a significant rise in the
amount of dihomogamma-linolenic acid, but plasma
levels of thromboxane and prostaglandins were not
changed. Some authors have not been able to dupli-
cate these beneficial clinical effects (17,18), and in
my uncontrolled clinical experience with over 50
cases, the results have been utiimpressive.
Other authors studied the effect of dietary sup-
plementation with EPA in the treatment of atopic
dermatitis. In a 12-week, double-blind, randomized
trial, 16 adults with AD were given 10 max-EPA
capsules daily (1.8 g EPA) and 15 controls were
given 10 olive oU capsules a day (19). Severity
scores assessed by the physician showed no statis-
tically significant difference between the active and
placebo groups. The patients' assessments, how-
ever, showed that max-EPA was better than pla-
cebo with regard to itch (P < 0.05), scale (P < 0.05),
and total symptom score (P < 0.02). No significant
difference was found between the groups with re-
gard to topical steroid use during the trial.
Phosphodiesterase Inhibitors
Hatiifin et al (20) have demonstrated that leuko-
cytes from patients with AD show elevated activity
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of cyclic adenosine 3',5'-tnonophosphate phos-
phodiesterase (PDE). The authors think that high
PDE activity may allow increased IgE production
as well as increased histamine release fî om baso-
phils £ind mast cells. They believe that this is a basic
defect of AD.
To my knowledge there are no controlled trials of
any known systemic PDE inhibitor since most of
these drugs are too toxic for general use. Baer (21)
advocates the use of papaverine, 150 mg twice a
day, on the grounds that it is significantly effective
in decreasing pruritus in patients with AD. The
agent is believed to be a nontoxic, mild vasodilator,
and has been in use since 1947. Baer (21) anecdot-
ally reported his therapy of "hundreds of patients
with moderately severe atopic dermatitis" and cur-
rently uses the 150-mg timed-release capstiles twice
and occasionally three times a day. He believes that
it reduces itching in the majority of cases of AD,
and in some patients "appears to have a truly strik-
ing effect." Baer noted that papaverine is an inhib-
itor of leukocyte PDE levels, citing the previous
work of Hanifin et ai.
Other PDE inhibitors such as caffeine, used as a
30% cream with 0.5% hydrocortisone, have been
reported to be more effective than 0.5% hydrocorti-
sone alone in patients with AD (22). I have been
able to locate nothing more in the literature on their
use. I have found the use of papaverine to be with-
out substantisd effect in an uncontrolled series of 50
children with atopic eczema. In addition, 30% caf-
feine cream was without effect in localized areas of
atopic eczema in my experience, and the potential
for adverse reaction from percutaneous absorption
appears significant.
House Dust Mite Allergy
Seventy-five percent of children with AD are sensi-
tized to the house dust mite (HDM) by age 10 years.
Beck and Hagdrup (23) analyzed 210 patients with
AD and a positive prick test toward the animal
{Dermatophagoides pteronyssimus), finding a high
prevalence were bom between May and November,
compared with the expected distribution. Exposure
to the mite is much more common during these
months.
Vickers (24) noted that cell-mediated immunity
to house dust mite antigen was demonstrated in 11
of 16 patients with atopic eczema compared to 2 of
14 controls. He reviewed studies showing the diffi-
culty in hyposensitizing patients to the antigen, and
emphasized his work with its avoidance using nat-
amycin (Tymosil). This agent kills Aspergillus,
which is the staple food of the house mite. Vickers
believes house dust mite eczema is related to early
morning fiares, high IgE levels, and positive radio-
allergosorbent test (RAST). It may also be associ-
ated with a respiratory allergy. He treated 11 chil-
dren in an open study in which natamycin was used
throughout the house for a six-month period. Three
children showed no change, three had moderate im-
provement, and the remaining five (45%) had dra-
matic improvement in both skin and respiratory al-
lergies.
Norris et al (25) showed that house dust mite
could play a role in the pathogenesis of atopic ec-
zema. Application of house dust mite solution or
control to the antecubital or popliteal fossa showed
a marked delayed local reaction in one-third of pa-
tients with AD due to house dust mite only. Further
evidence supporting the role of the atiimal in the ev-
olution of atopic dermatitis is the fact that HDM-
specific IgE mirrors disease severity. Several un-
controlled studies show that avoiding the mite
improves AD.
Desperation or Experimental Therapy
For patients whose severe eczema is unresponsive
to topical and intermittent use of oral corticoste-
roids, UV, and dietary supplementation, systemic
cytotoxic agents may be useful. Morrison and
Schulz (26) treated tiine adult patients with intracta-
ble, severe AD, using cyclophosphamide, 100 mg
dciily, in eight cases, and azathioprine, 50 to 100 mg
daily, in the other. One patient treated with cyclo-
phosphamide was subsequently given azathioprine.
Patients were monitored carefuUy for development
of leukopenia and thrombocytopenia. All reported
remarkable improvement in an average of 13 weeks.
The percentage of skin involvement, which before
therapy had averaged 80%, fell to an average of 7%
during therapy. After the drugs were stopped, re-
missions varied from 1 to 60 months (average 24
mo). I have no experience with these drugs in adults
or children.
Chloroquin, 125 to 250 mg/day for three to six
months, was used by Doritig and Kreppel (27) to
treat 62 patients suffering from AD. In 46 the ther-
apy resulted in such significant improvement that
all systemic and other topical agents could be dis-
continued. Eight others reported substantial im-
provement but still used topical corticosteroids.
Hanifin's group (28) evaluated 18 patients with
AD who were treated with injections of 50 mg TP-5
(thymopoietin) or placebo three times weekly.
Younger patients (age <34 yrs) responded to TP-5
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with much greater improvement in severity scores
than those older than age 34 who received the hor-
mone, or patients of either age group who were
given placebo (P < 0.05). Immunologic abnormali-
ties also reverted toward normal in patients given
TP-5.
In a similar study. Harper et al (29) used thy-
mostimulin (TP-1) in a double blind, controlled
study of 29 adults with severe lifelong AD. Treat-
ment consisted of twice-weekly injections of 1.5
mg/kg for 10 weeks. A 20% reduction in clinical se-
verity was noted when TP-1 was compared to pla-
cebo; however, T8 lymphopenia, high IgE levels,
and high blood eosinophilia were unchanged in spite
of the clinical improvement.
Finally, I wotild like to discuss the dermatologic
applications of cyclospwrine in AD. Vanjoost et al
(30) were the first to note the beneficial effects of
the drug on severe disease. They treated two pa-
tients with severe drug-resistant disease with 5
mg/kg/day of cyclosporine, and near complete re-
mission (>SK)%) was observed in both after four
weeks of therapy. There was no correlation be-
tween trough blood levels and degree of improve-
ment. After discontinuing cyclosfwrine, a gradual
recurrence of lesions and pruritus was observed
within three weeks.
Members of the Department of Dermatology at
The University of Michigan treated five patients
with low-dose cyclosporine and noted similarly
good responses with a minimal amount of side ef-
fects (AK Gupta, JJ Voorhees, K Cooper, et al,
personal communications, 1988). A double-blind,
controlled study is now under way in our institution
on low-dose cyclosporine in the treatment of AD.
No pediatric patients, to my knowiedge, have been
treated systemically with this drug, however.
De Prost reported on his recent study of topical
cyclosporine at the third international symposium
on atopic dermatitis held in Oslo, Norway. This was
a 20-patient, double-blind, controlled, paired com-
parison of a 10% topical cyclosporine gel with gel
minus CSA. Patients were evaluated at 14 days for
pruritus, erythema, lichenification, and scale xero-
sis. De Prost reported that all values improved in a
statistically significant fashion, and that blood lev-
els of cyclosporine were undetectable at topical
dosing levels of 10 mg/kg.
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